Last reviewed · How we verify

Lidocaine gel 2% — Competitive Intelligence Brief

Lidocaine gel 2% (Lidocaine gel 2%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesia/Pain Management.

marketed Local anesthetic Voltage-gated sodium channels Anesthesia/Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Lidocaine gel 2% (Lidocaine gel 2%) — Atlantic Health System. Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lidocaine gel 2% TARGET Lidocaine gel 2% Atlantic Health System marketed Local anesthetic Voltage-gated sodium channels
intraarticular injection with ropivacaine intraarticular injection with ropivacaine Hvidovre University Hospital marketed Local anesthetic Voltage-gated sodium channels
lamotrigine (generic Teva) lamotrigine (generic Teva) University of Maryland, Baltimore marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition
Hyperbaric bupivacaine+Morphine Hyperbaric bupivacaine+Morphine Fundación Pública Andaluza Progreso y Salud marketed Local anesthetic + opioid combination Voltage-gated sodium channels (bupivacaine); mu opioid receptors (morphine)
Control (bupivacaine) Control (bupivacaine) Kasr El Aini Hospital marketed Local anesthetic (amide) Voltage-gated sodium channels
Bupivacaine Liposomes(BL) Bupivacaine Liposomes(BL) Huazhong University of Science and Technology marketed Local anesthetic (liposomal formulation) Voltage-gated sodium channels
Lidocaine (drug) Lidocaine (drug) Daniel A Tonetti, MD marketed Local anesthetic Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

  1. University of California, San Diego · 3 drugs in this class
  2. Durect · 3 drugs in this class
  3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
  4. Wake Forest University Health Sciences · 3 drugs in this class
  5. Medical University of Vienna · 3 drugs in this class
  6. Imperial College London · 2 drugs in this class
  7. Hvidovre University Hospital · 2 drugs in this class
  8. Innocoll · 2 drugs in this class
  9. George Washington University · 2 drugs in this class
  10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lidocaine gel 2% — Competitive Intelligence Brief. https://druglandscape.com/ci/lidocaine-gel-2. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: